Abbott ID NOW COVID-19 is a molecular point-of-care test system for the detection of patients infected with Covid-19. It facilitates qualitative detection of the nucleic acid of SARS-CoV-2 virus in Covid-19 suspected patient.
Abbott Diagnostics provides integrated automation systems, assays and informatics to optimise laboratory operations and improve productivity.
The company’s resourceful advocates provide customised optimisation solutions to address challenges and take a holistic, enterprise-level view to meet rising demand for efficiency and accuracy in the laboratory environment.
Abbott Diagnostics also provides intelligent actionable insights through its harmonised family of innovative systems. Its robust processes and informatics enablers consistently analyse and monitor client data to incase laboratory productivity. Its Alinity and AlinIQ solutions provide a unified experience across multiple areas of the laboratory, from immunoassay to haematology, transfusion and point-of-care.
Informatics services for medical device laboratories
Abbott Diagnostics’ AlinIQ informatics solution consistently analyses and monitors data and highlights areas for productivity optimisation.
Its consultative insights and predictive services provide continuity and standardisation to the laboratory, helping increase the flexibility and efficiency needed to meet the changing demands of the medical device industry.
The company utilises this data to develop automation solutions to improve laboratory performance such as reducing turnaround times and the total cost of ownership.
Abbott Diagnostics’ technical solution design teams are creative problem solvers that streamline and simplify workflows. Using the company’s extensive experience, customers can meet the demands of their laboratories with reduced risk and ensured continuity of services. Abbott Diagnostics supports customers with flexible, customised automation, ranging from sample tubes to open connectivity.
The company also ensures that laboratories consistently meet clients’ key performance indicators in an efficient and safe way. It uses integrated automated software and hardware to reduce manual processes and waste, reducing exposure to biohazards and optimising the use of space.
Fast, accurate diagnosis and support
Abbott Diagnostics offers support and solution optimisation that is aligned with clients’ goals. Its robust processes, informatics and service experts help clients navigate changes in the healthcare industry, resulting in fast and accurate diagnosis.
The company’s tools provide insight to medical diagnostic instruments, tests, automation and informatics solutions for hospitals, reference labs, blood centres, emergency departments, physician offices and clinics.
Assessment of laboratory assays and instruments
Abbott Diagnostics enables laboratories to objectively and quantitatively assess the performance of assays and instruments. It also reduces costs by supplying and controlling material, labour and quality failure investigations.
The company’s instruments and technologies improve patient flow and standardisation by extending the linear ranges of enzyme assays for better first-time results and fewer re-runs. Only 32µL of sample is needed for an eight-test metabolic panel and the pressure differential technology detects clots.
Abbott Diagnostics also standardises integrity reporting and results, which provides a fast turnaround time. Productivity is enhanced through inventory management and automated maintenance.
Coagulation testing systems, analysers and reagents
Abbott Diagnostics’ coagulation system and reagents integrate with the company’s core laboratory solutions to optimise workflow. The CP3000 is designed for high-throughput in-vitro diagnostics, utilising advanced automation to process up to 400 PT tests an hour.
With a small footprint of 0.544m2, CP3000 is suitable for both automation track and standalone environments. Its touchscreen interface makes it simple to operate.
Haematology analysers and samplers
Abbott Diagnostics provides a comprehensive portfolio of haematology solutions, analysis, reagents, calibrators and controls for laboratories with a wide range of testing volumes.
The Alinity h-series is designed to increase efficiency in the clinical laboratory. These customisable harmonised systems aim to increase the capacity and flexibility of medical device laboratories, as well as address uncertainty in the healthcare environment due to ageing populations and performance pressures such as consolidation and managing costs.
The units integrate haematology workflow with bi-directional internal conveyors that complete blood counts (CBC) with six-part white blood cell (WBC) differential and several parameters using advanced multi-angle polarised scatter separation (MAPSS) technology. With a throughput of 125 CBCs per square metre, the design incorporates additional angular intervals of light scatter to improve the differentiation of WBC, red blood cells (RBC) and platelets as they pass through the optical flow cell.
The Alinity h-series technology is combined with multi-paradigm numerical computer tools, graph adaptive clustering (GAC), a machine-learning cell classifier and a Gaussian mixture model (GMM).
Abbott aims to help people live healthy lives by bringing information, medicines and breakthroughs to maintain and manage heart health.
The company creates innovative diagnostic, medical device and nutrition products, as well as generic pharmaceuticals to help increase community health.
Abbott has a workforce of 99,000 experts that support clients in more than 150 countries.
Amplatzer Piccolo™ Occluder is one of the first trans-catheter treatments to be approved for the treatment of patent ductus arteriosus (PDA), a common congenital disorder that results in a life-threatening opening in the heart of premature infants and newborns.